Pristiq Drug Class
Pristiq (desvenlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) 1.
Mechanism and Classification
Desvenlafaxine belongs to the SNRI class of antidepressants, which work by inhibiting the presynaptic reuptake of both serotonin and norepinephrine in the central nervous system 1. The exact mechanism of its antidepressant action is thought to be related to the potentiation of these neurotransmitters through inhibition of their reuptake 1.
The SNRI class includes several medications currently marketed in the United States:
- Venlafaxine
- Desvenlafaxine (Pristiq)
- Duloxetine
- Levomilnacipran 2
Relationship to Venlafaxine
Desvenlafaxine is structurally the major active metabolite (O-desmethylvenlafaxine) of the antidepressant venlafaxine 1, 3. Despite this metabolic relationship, desvenlafaxine is marketed as a distinct medication with its own FDA approval for major depressive disorder.
Pharmacological Characteristics
As an SNRI, desvenlafaxine is a potent and selective inhibitor of both serotonin and norepinephrine reuptake 1. Non-clinical studies demonstrate that desvenlafaxine lacks significant affinity for muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors, and it does not inhibit monoamine oxidase (MAO) 1.
The medication has sufficiently long elimination half-life to permit single daily dosing 2, which distinguishes it from immediate-release venlafaxine that may require multiple daily doses.
Clinical Context
The SNRI class, including desvenlafaxine, is recognized in clinical guidelines as effective treatment for various conditions including major depressive disorder, generalized anxiety disorder, and neuropathic pain 4, 2. SNRIs are generally considered alongside SSRIs as first-line antidepressant options due to their favorable adverse effect profiles compared to older antidepressants like tricyclics 5.